SPOTLIGHT: Pertuzumab slows breast cancer in study


Roche announced that a combination of Herceptin and pertuzumab slowed the spread of breast cancer. Pertuzumab is the first in a new class of agents known as HER dimerization inhibitors. HDIs block the ability of the HER2 receptor to collaborate with other HER receptor family members. Report

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.